Celltrion to present at the 44th Annual J.P. Morgan Healthcare Conference
INCHEON,
Celltrion's presentation and fireside chat are scheduled for
About Celltrion, Inc.
Celltrion, Inc. is a leading biopharmaceutical company that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. Celltrion, Inc. is a pioneer in the biosimilar space, having launched the world's first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Built on trust through our fully integrated capabilities – from advanced R&D and in-house manufacturing to a reliable global supply network – we continue moving toward innovation as we work to ensure consistent availability of affordable, trusted, and high-quality biosimilars and biologics for patients and healthcare systems across the globe.
For more information, please visit our website www.celltrion.com/en-us and stay updated with our latest news and events on our social media - LinkedIn, Instagram, X, and Facebook.
US--25-00145
For further information please contact:
Global PR Team
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/celltrion-to-present-at-the-44th-annual-jp-morgan-healthcare-conference-302654432.html
SOURCE Celltrion
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Poppies® Invites Families to Share a Little Sweetness Through Grown to Share
- EquipmentShare.com Inc. Notice of September 21, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
- Hansen Technologies Receives Frost & Sullivan's 2026 European Customer Value Leadership Recognition for Excellence in Meter Data Management Innovation
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share